Data on 2-year survival in the phase III CheckMate 067 trial testing nivolumab plus ipilimumab showed a slight survival benefit for the combination over nivolumab monotherapy—but the difference may not be dramatic enough to justify using the combination given the added side effects.
http://ift.tt/2ri98VO
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου